Pfizer Corporation

Other

Massachusetts Institute of Technology

The General Hospital Corporation

Epizyme, Inc.

Xtuit Pharmaceuticals, Inc.

Lawrence Alan Reiter

Michael John Munchhof

Christopher Scott Jones

Susan D La Greca

Qifang Li

Gaston O Daumy

Robert Samuel Langer

Lawrence S Melvin, Jr

Kenneth William Duncan

Wayne E Barth

Donald E Chickering, Iii

Martin James Wythes

Kevin Koch

John Emmerson Campbell

Rakesh K Jain

Kelvin Cooper

Edward F Kleinman

Thomas C Crawford

Ralph P Robinson

Mark Carl Noe

Kevin Daniel Freeman-Cook

Darren Martin Harvey

Alan Crane

Peter A McCarthy

John L LaMattina

Sally Gut Ruggeri

Megan Alene Cloonan Foley

Dai Fukumura

Michael Thomenius

Peter Blume-Jensen

Rong Tong

Joao Incio

Vikash Pal Singh Chauhan

Paul W Kopesky

Compounds of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, G1, G2, Q, Q, Q, and (II) are defined as set forth in the specification, as are uses of compounds of Formula I to treat a disease, disorder, or condition such as cancer in a subject.

Substituted indoles and methods of use thereof

Provided herein are polymers, pH-sensitive polymers and/or linkers; conjugates comprising said polymers and/or linkers, optionally, coupled to one or more agents and/or targeting moieties; and particles (e.g., nanoparticles comprising the aforesaid polymers, linkers and/or conjugates), which can be used to enhance the delivery and/or efficacy of one or more agents in a subject.

Polyacetal polymers, conjugates, particles and uses thereof

The present invention relates to a compound of the Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

Benzimidazole derivatives

The present invention relates to triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione; metalloproteinase inhibitors of the formulawherein X, A, Y, B, G, W, and Rare as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.

Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors

Pyrimidine-2,4,6-trione metalloproteinase inhibitors

3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides

3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides

A compound of the formula ##STR1## wherein Y and R.sup.1 are defined in the specification, useful in the treatment of arthritis or cancer and other diseases involving selective inhibition of matrix metalloproteinase-13.

Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives

A compound of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, synergy with cytotoxic anticancer agents, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, in combination with standard NSAID'S and analgesics and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinim, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

Phosphinate based inhibitors of matrix metalloproteases

(4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides

Para-nitroanilide peptides

Benzopyran and related LTB.sub.4 antagonists

Paranitroaniline peptides

Antiinflammatory and analgesic oxindole prodrugs of the formula ##STR1## wherein R.sup.10, R.sup.11, R.sup.12 and R.sup.13 are hydrogen, alkyl or halogen and R is methyleneoxyalkanoyl, methyleneoxyalkenoyl or alkenoyl.

Prodrugs of antiinflammatory 3-acyl-2-oxindole-1-carboxamides

Growing community of inventors

Mystic, CT, United States of America

Lawrence Alan Reiter